Moderna shares jump 6% on renewed interest from Hantavirus vaccine research and strong Q1 results.

Moderna's stock rose about 6% following reports of a Hantavirus outbreak and the company's early-stage mRNA vaccine research targeting the virus. This surge extends Moderna's strong 2026 performance, with shares up 95% year-to-date, outperforming Pfizer and Novavax. The rally is driven by renewed retail interest and solid fundamentals, including a Q1 revenue beat and reaffirmed full-year guidance. Investors are also watching for the August 5 FDA decision on Moderna's seasonal flu vaccine, which could expand its commercial portfolio beyond COVID-19 products.